Neurocrine Biosciences, Inc.
NBIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $13,705 | $12,873 | $11,442 | $8,057 |
| - Cash | $233 | $251 | $263 | $341 |
| + Debt | $455 | $428 | $263 | $440 |
| Enterprise Value | $13,927 | $13,050 | $11,442 | $8,157 |
| Revenue | $2,355 | $1,887 | $1,489 | $1,134 |
| % Growth | 24.8% | 26.8% | 31.3% | – |
| Gross Profit | $2,321 | $1,847 | $1,466 | $1,119 |
| % Margin | 98.6% | 97.9% | 98.4% | 98.7% |
| EBITDA | $640 | $416 | $265 | $138 |
| % Margin | 27.2% | 22% | 17.8% | 12.2% |
| Net Income | $341 | $250 | $155 | $90 |
| % Margin | 14.5% | 13.2% | 10.4% | 7.9% |
| EPS Diluted | 3.29 | 2.47 | 1.56 | 0.92 |
| % Growth | 33.2% | 58.3% | 69.6% | – |
| Operating Cash Flow | $595 | $390 | $339 | $257 |
| Capital Expenditures | -$38 | -$28 | -$17 | -$23 |
| Free Cash Flow | $557 | $362 | $323 | $233 |